Browsing by Author "Silva, Berenice"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America COVID-19 in MS and NMOSD patients in LATAM
    (2021) Alonso, Ricardo; Silva, Berenice; Garcea, Orlando; Correa Diaz, Patricio E.; dos Passos, Giordani Rodrigues; Ramirez Navarro, Deyanira A.; Garcia Valle, Luis A.; Rodriguez Salinas, Luis C.; Negrotto, Laura; Luetic, Geraldine; Tkachuk, Veronica A.; Miguez, Jimena; Diaz de Bedoya, Fernando Hamuy; Goiry, Lorna Galleguillos; Ramirez Sanchez, Nicia E.; Burgos, Marcos; Steinberg, Judith; Balbuena, Maria E.; Monterrey Alvarez, Priscilla; Lopez, Pablo A.; Ysrraelit, Maria C.; Leon, Rosalba A.; Cohen, Aron Benzadon; Gracia, Fernando; Molina, Omaira; Casas, Magdalena; Deri, Norma H.; Pappolla, Agustin; Patrucco, Liliana; Cristiano, Edgardo; Tavolini, Dario; Nadur, Debora; Granda, Ana M. Toral; Weiser, Roberto; Cassara, Fatima Pagani; Sinay, Vladimiro; Carcamo Rodriguez, Claudia; Lazaro, Luciana G.; Menichini, Maria L.; Piedrabuena, Raul; Orozco Escobar, Geraldine; Carra, Adriana; Chertcoff, Anibal; Santos Pujols, Biany; Vrech, Carlos; Tarulla, Adriana; Carvajal, Rene; Mainella, Carolina; Becker, Jefferson; Peeters, Liesbet M.; Walton, Clare; Alonso Serena, Marina; Nunez, Sebastian; Rojas, Juan, I
    Background: There is no data regarding COVID-19 in Multiple Sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients in Latin America. Objective: The objective of this study was to describe the clinical characteristics and outcomes of patients included in RELACOEM, a LATAM registry of MS and NMOSD patients infected with COVID-19. Methods: RELACOEM is a longitudinal, strictly observational registry of MS and NMOSD patients who suffer COVID-19 and Dengue in LATAM. Inclusion criteria to the registry were either: (1) a biologically confirmed COVID-19 diagnosis based on a positive result of a COVID-19 polymerase chain reaction (PCR) test on a naso-pharyngeal swab; or (2) COVID-19-typical symptoms (triad of cough, fever, and asthenia) in an epidemic zone of COVID-19. Descriptive statistics were performed on demographic and clinical variables. The cohort was later stratified for MS and NMOSD and univariate and multivariate logistic regression analysis was performed to identify variables associated with hospitalizations/intensive critical units (ICU) admission. Results: 145 patients were included in the registry from 15 countries and 51 treating physicians. A total of 129 (89%) were MS patients and 16 (11%) NMOSD. 81.4% patients had confirmed COVID-19 and 18.6% were suspected cases. 23 (15.8%) patients were hospitalized, 9 (6.2%) required ICU and 5 (3.4 %) died due to COVID-19. In MS patients, greater age (OR 1.17, 95% CI 1.05 - 1.25) and disease duration (OR 1.39, 95%CI 1.14-1.69) were associated with hospitalization/ICU. In NMOSD patients, a greater age (54.3 vs. 36 years, p=<0.001), increased EDSS (5.5 vs 2.9, p=0.0012) and disease duration (18.5 vs. 10.3 years, p=0.001) were significantly associated with hospitalization/ICU. Conclusion: we found that in MS patients, age and disease duration was associated with hospitalization and ICU admission requirement, while age, disease duration and EDSS was associated in NMOSD.
  • No Thumbnail Available
    Item
    The real-world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody-associated disease criteria in a Latin American cohort
    (2024) Contentti, Edgar Carnero; Pestchanker, Claudia; Ciampi, Ethel; Suarez, Sheila Castro; Zamalloa, Cesar Caparo; Marques, Vanesa Daccach; Messias, Katharina; Gortari, Jose Ignacio; Tkachuk, Veronica; Silva, Berenice; Mainella, Carolina; Reyes, Saul; Toro, Jaime; Rodriguez, Juan; Correa-Diaz, Edgar; Rojas, Juan I.; Paul, Friedemann
    Background and Purpose: The diagnostic criteria for myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-associated disease (MOGAD) were published in 2023. We aimed to determine the performance of the new criteria in Latin American (LATAM) patients compared with the 2018 criteria and explore the significance of MOG-IgG titers in diagnosis. Methods: We retrospectively reviewed the medical records of LATAM (Argentina, Chile, Brazil, Peru, Ecuador, and Colombia) adult patients with one clinical MOGAD event and MOG-IgG positivity confirmed by cell-based assay. Both 2018 and 2023 MOGAD criteria were applied, calculating diagnostic performance indicators. Results: Among 171 patients (predominantly females, mean age at first attack = 34.1 years, mean disease duration = 4.5 years), 98.2% patients met the 2018 criteria, and of those who did not fulfill diagnostic criteria (n = 3), all tested positive for MOG-IgG (one low-positive and two without reported titer). Additionally, 144 (84.2%) patients met the 2023 criteria, of whom 57 (39.5%) had MOG-IgG+ titer information (19 clearly positive and 38 low-positive), whereas 87 (60.5%) patients had no MOG-IgG titer. All 144 patients met diagnostic supporting criteria. The remaining 27 patients did not meet the 2023 MOGAD criteria due to low MOG-IgG (n = 12) or lack of titer antibody access (n = 15), associated with the absence of supporting criteria. The 2023 MOGAD criteria showed a sensitivity of 86% (95% confidence interval = 0.80-0.91) and specificity of 100% compared to the 2018 criteria. Conclusions: These findings support the diagnostic utility of the 2023 MOGAD criteria in an LATAM cohort in real-world practice, despite limited access to MOG-IgG titration.